{"id":9677,"date":"2026-09-01T16:42:02","date_gmt":"2026-09-01T14:42:02","guid":{"rendered":"https:\/\/fhu-premimpact.org\/?post_type=publication&#038;p=9677"},"modified":"2026-10-12T16:45:42","modified_gmt":"2026-10-12T14:45:42","slug":"pregnancy-related-effect-on-elexacaftor-tezacaftor-and-ivacaftor-pharmacokinetics-in-women-with-cystic-fibrosis","status":"publish","type":"publication","link":"https:\/\/fhu-premimpact.org\/en\/publications\/pregnancy-related-effect-on-elexacaftor-tezacaftor-and-ivacaftor-pharmacokinetics-in-women-with-cystic-fibrosis\/","title":{"rendered":"Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Abstract<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Aim:<\/strong> The number of pregnancies among women with cystic fibrosis (wwCF) has steadily increased over the past decade. However, the pharmacokinetics (PK) of elexacaftor-tezacaftor-ivacaftor (ETI) during gestation remains uncharacterized, despite its widespread use in this population. To date, no clinical trials have investigated the effectiveness, safety or PK profiles of ETI during pregnancy. Given the significant physiological changes that occur throughout gestation, which can alter drug PK, characterizing how pregnancy impacts ETI exposure represents a key step towards informing appropriate dosing strategies. Therefore, the aim of this analysis was to assess pregnancy effect on ETI PK.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Method:<\/strong> As part of the French national observational cohort study, therapeutic drug monitoring was performed in 145 wwCF, including 14 pregnant participants. PK profiles for each compound were characterized using the previously published ETI adult population PK model from the same cohort, with model development and evaluation performed using Monolix\u00ae software.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Results:<\/strong> A total of 294 plasma samples, including 47 collected from pregnant participants, were drawn during routine clinical care. Pregnancy was found to significantly increase the apparent clearance of tezacaftor (0.97 to 1.44 L\/h) and of ivacaftor (9.64 to 11.36 L\/h), indicating a decrease in systemic exposure.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Conclusion:<\/strong> These findings raise important questions regarding whether decreased total tezacaftor and ivacaftor exposure may compromise the sustained treatment efficacy. The necessity for dose adjustments during pregnancy remains to be evaluated from a PK (unbound ETI concentrations) and pharmacodynamic (clinical effectiveness) perspective, thus warranting further studies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Keywords:<\/strong> cystic fibrosis; elexacaftor\u2013tezacaftor\u2013ivacaftor; population pharmacokinetics; pregnancy.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Br J Clin Pharmacol. 2026 Sep;92(9):3202-3213. <\/p>\n","protected":false},"featured_media":0,"template":"","class_list":["post-9677","publication","type-publication","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis - FHU Prem&#039;IMPACT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fhu-premimpact.org\/en\/publications\/pregnancy-related-effect-on-elexacaftor-tezacaftor-and-ivacaftor-pharmacokinetics-in-women-with-cystic-fibrosis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis - FHU Prem&#039;IMPACT\" \/>\n<meta property=\"og:description\" content=\"Br J Clin Pharmacol. 2026 Sep;92(9):3202-3213.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fhu-premimpact.org\/en\/publications\/pregnancy-related-effect-on-elexacaftor-tezacaftor-and-ivacaftor-pharmacokinetics-in-women-with-cystic-fibrosis\/\" \/>\n<meta property=\"og:site_name\" content=\"FHU Prem&#039;IMPACT\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-12T14:45:42+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/publications\\\/pregnancy-related-effect-on-elexacaftor-tezacaftor-and-ivacaftor-pharmacokinetics-in-women-with-cystic-fibrosis\\\/\",\"url\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/publications\\\/pregnancy-related-effect-on-elexacaftor-tezacaftor-and-ivacaftor-pharmacokinetics-in-women-with-cystic-fibrosis\\\/\",\"name\":\"Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis - FHU Prem&#039;IMPACT\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/#website\"},\"datePublished\":\"2026-09-01T14:42:02+00:00\",\"dateModified\":\"2026-10-12T14:45:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/publications\\\/pregnancy-related-effect-on-elexacaftor-tezacaftor-and-ivacaftor-pharmacokinetics-in-women-with-cystic-fibrosis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/publications\\\/pregnancy-related-effect-on-elexacaftor-tezacaftor-and-ivacaftor-pharmacokinetics-in-women-with-cystic-fibrosis\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/publications\\\/pregnancy-related-effect-on-elexacaftor-tezacaftor-and-ivacaftor-pharmacokinetics-in-women-with-cystic-fibrosis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\",\"item\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/publications\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/\",\"name\":\"FHU PREM'IMPACT\",\"description\":\"Perinatal inflammation and prematurity\",\"publisher\":{\"@id\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/#organization\",\"name\":\"FHU PREM'IMPACT\",\"url\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fhu-premimpact.org\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/logo-grand-centre-fhupremimpact.jpg\",\"contentUrl\":\"https:\\\/\\\/fhu-premimpact.org\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/logo-grand-centre-fhupremimpact.jpg\",\"width\":1280,\"height\":720,\"caption\":\"FHU PREM'IMPACT\"},\"image\":{\"@id\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.instagram.com\\\/fhupremimpact\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/fhu-prem-impact-ap-hp-inserm-universit-paris-cit-70b911253\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis - FHU Prem&#039;IMPACT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fhu-premimpact.org\/en\/publications\/pregnancy-related-effect-on-elexacaftor-tezacaftor-and-ivacaftor-pharmacokinetics-in-women-with-cystic-fibrosis\/","og_locale":"en_US","og_type":"article","og_title":"Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis - FHU Prem&#039;IMPACT","og_description":"Br J Clin Pharmacol. 2026 Sep;92(9):3202-3213.","og_url":"https:\/\/fhu-premimpact.org\/en\/publications\/pregnancy-related-effect-on-elexacaftor-tezacaftor-and-ivacaftor-pharmacokinetics-in-women-with-cystic-fibrosis\/","og_site_name":"FHU Prem&#039;IMPACT","article_modified_time":"2026-10-12T14:45:42+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fhu-premimpact.org\/en\/publications\/pregnancy-related-effect-on-elexacaftor-tezacaftor-and-ivacaftor-pharmacokinetics-in-women-with-cystic-fibrosis\/","url":"https:\/\/fhu-premimpact.org\/en\/publications\/pregnancy-related-effect-on-elexacaftor-tezacaftor-and-ivacaftor-pharmacokinetics-in-women-with-cystic-fibrosis\/","name":"Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis - FHU Prem&#039;IMPACT","isPartOf":{"@id":"https:\/\/fhu-premimpact.org\/en\/#website"},"datePublished":"2026-09-01T14:42:02+00:00","dateModified":"2026-10-12T14:45:42+00:00","breadcrumb":{"@id":"https:\/\/fhu-premimpact.org\/en\/publications\/pregnancy-related-effect-on-elexacaftor-tezacaftor-and-ivacaftor-pharmacokinetics-in-women-with-cystic-fibrosis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fhu-premimpact.org\/en\/publications\/pregnancy-related-effect-on-elexacaftor-tezacaftor-and-ivacaftor-pharmacokinetics-in-women-with-cystic-fibrosis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fhu-premimpact.org\/en\/publications\/pregnancy-related-effect-on-elexacaftor-tezacaftor-and-ivacaftor-pharmacokinetics-in-women-with-cystic-fibrosis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/fhu-premimpact.org\/en\/"},{"@type":"ListItem","position":2,"name":"Publications","item":"https:\/\/fhu-premimpact.org\/en\/publications\/"},{"@type":"ListItem","position":3,"name":"Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis"}]},{"@type":"WebSite","@id":"https:\/\/fhu-premimpact.org\/en\/#website","url":"https:\/\/fhu-premimpact.org\/en\/","name":"FHU PREM'IMPACT","description":"Perinatal inflammation and prematurity","publisher":{"@id":"https:\/\/fhu-premimpact.org\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fhu-premimpact.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fhu-premimpact.org\/en\/#organization","name":"FHU PREM'IMPACT","url":"https:\/\/fhu-premimpact.org\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/","url":"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg","contentUrl":"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg","width":1280,"height":720,"caption":"FHU PREM'IMPACT"},"image":{"@id":"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.instagram.com\/fhupremimpact\/","https:\/\/www.linkedin.com\/in\/fhu-prem-impact-ap-hp-inserm-universit-paris-cit-70b911253\/"]}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false,"twentytwenty-fullscreen":false},"uagb_author_info":{"display_name":"Laurence Lecomte","author_link":"https:\/\/fhu-premimpact.org\/en\/author\/"},"uagb_comment_info":0,"uagb_excerpt":"Br J Clin Pharmacol. 2026 Sep;92(9):3202-3213.","_links":{"self":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/publication\/9677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/media?parent=9677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}